[32] found that exendin-4 mitigated resistance to the androgen receptor inhibitor enzalutamide in prostate cancer via the PI3K/AKT/mTOR pathway, suggesting that a combination of exendin-4 with enzalutamide may be a more effective therapeutic option for advanced prostate cancer
Animal studies show mostly mild local irritation at injection sites
Medication safety experts at ISMP, an ECRI company, have identified common errors and provided guidance to help patients and clinicians get the most from these breakthrough treatments
Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jdar E, Kandler K, Rigas G, Wadden TA
Zhu T et al (2015) Glucagon like peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-B (NF-B) signaling pathway in mice
The medication mimics the naturally occurring GLP-1 hormone thats released in the gut after eating